Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
CELZ Creative Medical Technology Holdings says it has completed enrollment and treatment across the entire FDA-cleared ADAPT trial, including the opioid cohort, advancing celz-201/olastrocel toward RMAT evaluation and phase 3 planning.
Creative Medical Technology Holdings (CELZ) says it successfully completes enrollment and treatment across the entire FDA-cleared ADAPT trial, including the opioid cohort, advancing CELZ-201 (Olastrocel) toward RMAT evaluation and Phase 3 planning.